Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-hepatic and systemic chemotherapy with or without antibody for non-resectable liver metastases
2011-000273-31Phase 2Terminated
- Sponsor
- Herlev Hospital
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of cetuximab in hepatic metastasis and liver cancer (2 arms), sponsored by Herlev Hospital. Primary endpoint: Tumour response. Started May 2011; status: terminated.
02
Drugs
cetuximab
03
Conditions
hepatic metastasisliver cancer
Beyond the preview
Go deeper on 2011-000273-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000273-31.